Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10) designed for the treatment of Crohn's disease and ulcerative colitis.Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
This drug was developed by Bristol-Myers Squibb and Medarex.
References